ArticleNature communications2018
The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers.
0numbers the graph read from it
0cells of the map it votes in
114citing papers in PubMed
13.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
114 citing papers in PubMed, 186 citations in OpenAlex.
- CDKN2A deletion associated with poor prognosis in patients with TERT promoter wild-type, IDH wild-type glioblastoma.Brain tumor pathology · 2026Article
- SMARCAL1 is a candidate therapeutic target for ALT-positive tumors.Genes & development · 2026Article
- Comparison between molecular and histological IDH-wild-type glioblastoma and extensive subgroup analysis of IDH-wild-type astrocytic tumors without genomic glioblastoma-defining alterations.Journal of neuro-oncology · 2026Article
- Dual TERT promoter mutations in glioblastoma, IDH-wildtype: a case report with preclinical investigations.Brain tumor pathology · 2026Article
- SMARCAL1 is a targetable synthetic lethal therapeutic vulnerability in ATRX-deficient gliomas that use alternative lengthening of telomeres.Neuro-oncology · 2026Article
- Functional analysis of telomere maintenance mechanisms is more informative than immunohistochemistry for ATRX mutation interpretation in Gliomas.Acta neuropathologica communications · 2025Article
- The alternative lengthening of telomeres pathway through a DNA repair lens: mechanism and therapeutic opportunities.NAR cancer · 2025Review
- A retrospective study of 30 cases evaluating the efficacy and safety of anlotinib plus Temozolomide for recurrent/residual glioma from a single center.BMC cancer · 2025Article
- Characterization of the mutational status of glioblastoma and high-grade astrocytomas in a Latin American cohort.Scientific reports · 2025Article
- Distinct mechanisms underlying extrachromosomal telomere DNA generation in ALT cancers.Nucleic acids research · 2025Article
- Alternative Lengthening of Telomeres: The Need forInternational journal of molecular sciences · 2025Article
- Pan-cancer analysis reveals SMARCAL1 expression is associated with immune cell infiltration and poor prognosis in various cancers.Scientific reports · 2025Article
- Epidemiology and Outcome of Primary Central Nervous System Tumors Treated at King Hussein Cancer Center.Cancers · 2025Article
- Mechanisms and regulation of replication fork reversal.DNA repair · 2024Review
- Clinical and molecular features of patients with IDH1 wild-type primary glioblastoma presenting unexpected short-term survival after gross total resection.Journal of neuro-oncology · 2024Article
- The Role of Glia Telomere Dysfunction in the Pathogenesis of Central Nervous System Diseases.Molecular neurobiology · 2024Review
- Mechanisms of telomere maintenance and associated therapeutic vulnerabilities in malignant gliomas.Neuro-oncology · 2024Review
- Imaging predictors of 4q12 amplified and RB1 mutated glioblastoma IDH-wildtype.Journal of neuro-oncology · 2024Article
- Glioblastoma Therapy: Past, Present and Future.International journal of molecular sciences · 2024Review
- The C250T Mutation ofCancers · 2024Article
54 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 4 institutions in 2 countries.
Bill H DiplasThe Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, 27710, NC, USA.ORCID http://orcid.org/0000-0001-9248-7351
Xujun HeThe Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, 27710, NC, USA.
Jacqueline A Brosnan-CashmanDepartment of Pathology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, 21231, MD, USA.
Heng LiuThe Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, 27710, NC, USA.ORCID http://orcid.org/0000-0002-7106-1463
Lee H ChenThe Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, 27710, NC, USA.
Zhaohui WangThe Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, 27710, NC, USA.
Casey J MoureThe Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, 27710, NC, USA.
Patrick J KillelaThe Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, 27710, NC, USA.
Daniel B LoriauxThe Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, 27710, NC, USA.
Eric S LippThe Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, 27710, NC, USA.
Paula K GreerThe Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, 27710, NC, USA.
Rui YangThe Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, 27710, NC, USA.
Anthony J RizzoDepartment of Pathology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, 21231, MD, USA.
Fausto J RodriguezDepartment of Pathology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, 21231, MD, USA.ORCID http://orcid.org/0000-0001-8662-1219
Allan H FriedmanThe Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, 27710, NC, USA.
Henry S FriedmanThe Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, 27710, NC, USA.
Sizhen WangGenetron Health (Beijing) Co. Ltd, Beijing, 102208, China.
Yiping HeThe Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, 27710, NC, USA.
Roger E McLendonThe Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, 27710, NC, USA.
Darell D BignerThe Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, 27710, NC, USA.
Yuchen JiaoState Key Laboratory of Molecular Oncology, Laboratory of Cell and Molecular Biology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. jiaoyuchen@cicams.ac.cn.
Matthew S WaitkusThe Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, 27710, NC, USA. matthew.waitkus@duke.edu.ORCID http://orcid.org/0000-0002-7116-6978
Alan K MeekerDepartment of Pathology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, 21231, MD, USA. ameeker1@jhmi.edu.
Hai YanThe Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, 27710, NC, USA. hai.yan@duke.edu.
Duke Medical Center · USJohns Hopkins University · USDuke University · USChinese Academy of Medical Sciences & Peking Union Medical College · CN
Funding
Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI DONNA NIEDZWIECKI · 1985 to 2026
$174.8MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007171 · NIGMS · DUKE UNIVERSITY · PI KONTOS, CHRISTOPHER D · 1985 to 2021
$31.2MTRAINING IN AREAS FUNDAMENTAL TO CANCER RESEARCHT32CA009110 · NCI · JOHNS HOPKINS UNIVERSITY · PI MATUNIS, MICHAEL J., WEERARATNA, ASHANI T · 1985 to 2025
$13.1MTraining Program in Developmental & Stem Cell BiologyT32HD040372 · NICHD · DUKE UNIVERSITY · PI Terry H Lechler · 2001 to 2026
$8.9MMedical Scientist Training Program Training GrantT32GM145449 · NIGMS · DUKE UNIVERSITY · PI Christopher D Kontos · 2022 to 2026
$6.6MThe Role of IDH1 Mutations in Gliomagenesis and MetabolismR01CA140316 · NCI · DUKE UNIVERSITY · PI YAN, HAI · 2010 to 2019
$3.2MExploiting MTAP deletion for GBM therapeuticsR01NS101074 · NINDS · DUKE UNIVERSITY · PI HE, YIPING · 2017 to 2021
$1.7MRole of GLUD2 as a metabolic driver of gliomas with IDH1 mutationsR01NS096407 · NINDS · DUKE UNIVERSITY · PI ASHLEY, DAVID M. · 2016 to 2019
$1.4MBrain Tumor Targeting Using Tumor-Specific NeuroimmunologyR01NS086943 · NINDS · DUKE UNIVERSITY · PI SAMPSON, JOHN H., YAN, HAI · 2014 to 2017
$1.4MGenomic approaches to guide molecular classification of gliomaF30CA206423 · NCI · DUKE UNIVERSITY · PI DIPLAS, BILL H · 2016 to 2017
$75kNCI NIH HHS F30 CA206423NCI NIH HHS P30 CA014236NCI NIH HHS R01 CA140316NCI NIH HHS T32 CA009110NICHD NIH HHS T32 HD040372NIGMS NIH HHS T32 GM007171NIGMS NIH HHS T32 GM145449NINDS NIH HHS R01 NS096407NINDS NIH HHS R01 NS101074
Abstract
The majority of glioblastomas can be classified into molecular subgroups based on mutations in the TERT promoter (TERTp) and isocitrate dehydrogenase 1 or 2 (IDH). These molecular subgroups utilize distinct genetic mechanisms of telomere maintenance, either TERTp mutation leading to telomerase activation or ATRX-mutation leading to an alternative lengthening of telomeres phenotype (ALT). However, about 20% of glioblastomas lack alterations in TERTp and IDH. These tumors, designated TERTp
Indexed as
AdolescentAdultAgedAged, 80 and overBrain NeoplasmsCell Line, TumorDNA HelicasesFemaleGenomicsGlioblastomaHEK293 CellsHeLa CellsHumansIsocitrate DehydrogenaseMaleMiddle AgedDNA HelicasesIsocitrate DehydrogenaseSMARCAL1 protein, humanTelomeraseTERT protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.